A news blog, weblog for all
Submitted by lucky_pharmacist on Sat, 04/19/2008 - 10:56.
in
- lucky_pharmacist's blog
- Login or register to post comments
Dear friends I am experimenting one more activity here i.e. weblog-newsblog. I am posting some recent news in Pharma industry with their links. I'll defintely like to have your comments and suggestions for this...
Consumers' Average Prescription Drug Copay Drops as Generic Drug Use Grows
Last year marked the first time in at least five years that consumers paid less, on average, in their prescription drug copay, according to the 2007 Drug Trend Report released by pharmacy benefit manager Express Scripts. The average copay dropped 25 cents to $13.20 even as the average total cost of a prescription rose from $55.01 to $55.93. Read more
Pharma's Direct-to-Consumer Marketing Continues Shift to Physician Offices, Online Programs
As budgets for Direct-to-Consumer (DTC) marketing continue to shrink, the U.S. pharmaceutical industry must become more strategic and targeted when reaching out to consumers, according to Cegedim Dendrite's latest DTC Check-Up Survey. Read more
Pfizer, Avant ink $440M cancer vax deal
Avant Immunotherapeutics is pocketing a $40 million upfront fee and a $10 million equity stake from Pfizer in exchange for the worldwide rights to Avant's experimental brain cancer vaccine. And Avant could pocket $390 million in milestone paydays if all goes well with the drug's development. Read more
http://www.fiercebiotech.com/story/pfizer-avant-ink-440m-cancer-vax-deal/2008-04-17
Celgene's lung cancer drug granted European orphan drug status
Celgene International Sarl has announced that amrubicin hydrochloride has been designated as an orphan medicinal product by the European Commission for the treatment of small cell lung cancer following the favorable opinion of the European Medicines Agency's Committee for orphan medicinal products.
India eyes R&D opportunities
India-based drugs have made a name for themselves as makers of copycat drugs. When a developer's lucrative drug goes off-patent, Indian companies are guaranteed to swoop in and make a less-expensive knock-off of the therapy. It's a strategy that's definitly paid off for the developers. Read more
http://www.fiercebiotech.com/story/india-eyes-rd-opportunities/2008-04-17
Please write your comments and suggestions.
Every one should focus
This is an excellent idea. If you listen to Dr.Tipnis here
www.pharmainfo.net/video/interview-dr-tipnis-h-p
he is more concerned about Indian pharma students external knowledge. I sincerely don't agree with him, especially after going through all you guys talented posts .
Since all of your blogs are getting popular in pharma student community , i think every one should bring news items through your blog post. We should have balance on both news and scientific information
Focus is really needed
Thanks for your inspiring comment. I know many of the teachers and industry people are concerned about the knowledge superiority of Indian students. But with the emergence of sources like internet the information collection has become more and more simple and superior.
I'll definitely try to put some interesting blogs which all should be beneficial to all.
keep it up!
great effort by giving a different mode to the blogging styles. keep it up!
Its really nice to have you all suppoting such activities
Thank you Praseen, I know it’s good when you see something that’s new and also more if it helps you. I am just trying to blog in a way so that all of us can get some more benefit out of it.
You too are going great with many areas being touched in your blogs, you too keep it up.